FATE Fate Therapeutics Inc

$FATE 30-40% target, double the standard for 2+ failed therapy, and they are at 100% so far. 4 of 6 CRR is not hard to imagine based on what we know thus far. Ive been following, studying, and investing in FATE for over 11 years. Aside from JNJ deal and subsequent fallout I see the next FT819 readout as FATEs most important binary event in its history. It validates the platform in a signficant way, and would allow many more years of cancer research without shareholder dilution. This is all opinion, not investment advice, but with that said, i personally expect a solid run up before this data is released. The accumulation has been consistent at these levels.

$FATE The leading role of $FATE in the autoimmune CAR-T race became more prominent after $NVS and $BMY recently paused their autoimmune CAR-T programs, which caused patient deaths and severe toxicities. Fate Therapeutics (FT819 / FT839) has many unique advantages, including a quality-controlled iPSC master cell bank (millions of doses); CRISPR TRAC-targeted (non-viral); FDA CDRP & RMAT; full-speed enrollment for a pivotal phase 2 trial; mild or no conditioning chemotherapy; same-day outpatient discharge, which will dominate as the first mass-market, off-the-shelf, outpatient therapy for Lupus. Buy and hold strong! 🤑🤑🤑 Cheers! 🤞✌️

$FATE 2.27 or 2.59 doesnt really make a difference until out of that range. in “data loading mode”

$FATE i like this daily candle we are going to post today, typically a reversal signal for FATE the last few years. Also i apologize for my terrible TA and calling the sma at 2.16 the other week. Cant trust AI. I noticed last night its actually around 1.88, and we bounced right off of it today. A close in 1.90s is fine. $2 will come around again as we near Nov

$FATE ACR sept 9, Fate has now promised updated FT819 human data at ACR, including the conditioning-free patients.

$FATE A unanimous preference for FT819 over autologous CAR T emerged, due to immediate access, shorter hospitalization, less intensive preconditioning chemotherapy, and product consistency.

$FATE Morning All!! Just giving a shout out to all Fellow Longs - longtime pals, and to the new as well!

$FATE Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs, vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. In line with this decision, Caribou will implement workforce and cost reductions.

$FATE Morning All! Not gonna lie, I’m not happy about pre-market showing us under $2.00. Still holding though…

$FATE What the ICY HELL!?!?!? I stay away from the matket for one day and THIS happens! Who's in charge here? I DEMAND to speak to the manager!!!

$FATE IMO.....Hiring Jamie Harrell as SVP of marketing to build out commercial infrastructure is the exact playbook a biotech uses to de-risk an asset and create leverage for a buyout. However, this could be a multi-year setup, not an immediate catalyst unless upcoming clinical data is an absolute slam dunk next month.....that forces a buyer's hand early. Without that home run, the stock is likely dead money near $2.00 or lower due to a massive catalyst gap. The Phase 2 RECLAIM-LN trial for FT819 isn't slated to finish enrollment until H1 2028, meaning primary 26-week readout data won't arrive until late 2028. With a $30M quarterly burn rate, institutional money will likely stay sidelined until hard results emerge. More critically, if upcoming interim readouts show weak efficacy or severe safety flags, the buyout thesis evaporates and the stock will tank. Barring that slam-dunk data, expect the price to remain range-bound. Good Luck!

$FATE looks like it's going back to 1.5-1.6 levels. Such a crappy company. What a waste of time and money. Lowest levels since June. Ugghhh